Evidence map›Paper›PMID 36517751›Full record

ArticleMolecular medicine (Cambridge, Mass.)2022

MicroRNA composition of plasma extracellular vesicles: a harbinger of late cardiotoxicity of doxorubicin.

Justyna Totoń-Żurańska, Joanna Sulicka-Grodzicka, Michał T Seweryn, Ewelina Pitera, Przemysław Kapusta, Paweł Konieczny, Leszek Drabik, Maria Kołton-Wróż, Bernadeta Chyrchel, Ewelina Nowak and 3 more

Open access · goldAbstract read
In one paragraph

Article in Molecular medicine (Cambridge, Mass.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.6field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 2 countries.

Justyna Totoń-ŻurańskaCenter for Medical Genomics OMICRON, Jagiellonian University Medical College, ul. Kopernika 7C, 31-034, Krakow, Poland. justyna.toton-zuranska@uj.edu.pl.ORCID 0000-0001-5970-238X
Joanna Sulicka-GrodzickaDepartment of Rheumatology, Jagiellonian University Medical College, Krakow, Poland.
Michał T SewerynCenter for Medical Genomics OMICRON, Jagiellonian University Medical College, ul. Kopernika 7C, 31-034, Krakow, Poland.
Ewelina PiteraCenter for Medical Genomics OMICRON, Jagiellonian University Medical College, ul. Kopernika 7C, 31-034, Krakow, Poland.
Przemysław KapustaCenter for Medical Genomics OMICRON, Jagiellonian University Medical College, ul. Kopernika 7C, 31-034, Krakow, Poland.
Paweł KoniecznyCenter for Medical Genomics OMICRON, Jagiellonian University Medical College, ul. Kopernika 7C, 31-034, Krakow, Poland.
Leszek DrabikMedical College and John Paul II Hospital, Jagiellonian University, Krakow, Poland.
Maria Kołton-WróżCenter for Medical Genomics OMICRON, Jagiellonian University Medical College, ul. Kopernika 7C, 31-034, Krakow, Poland.
Bernadeta ChyrchelSecond Department of Cardiology, Jagiellonian University Medical College, Krakow, Poland.
Ewelina NowakDepartment of Internal Medicine and Gerontology, Jagiellonian University Medical College, Krakow, Poland.
Andrzej SurdackiSecond Department of Cardiology, Jagiellonian University Medical College, Krakow, Poland.
Tomasz GrodzickiDepartment of Internal Medicine and Gerontology, Jagiellonian University Medical College, Krakow, Poland.
Paweł P WołkowCenter for Medical Genomics OMICRON, Jagiellonian University Medical College, ul. Kopernika 7C, 31-034, Krakow, Poland.
Jagiellonian University · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe use of doxorubicin is associated with an increased risk of acute and long-term cardiomyopathy. Despite the constantly growing number of cancer survivors, little is known about the transcriptional mechanisms which progress in the time leading to a severe cardiac outcome. It is also unclear whether long-term transcriptomic alterations related to doxorubicin use are similar to transcriptomic patterns present in patients suffering from other cardiomyopathies.

methodsWe have sequenced miRNA from total plasma and extracellular vesicles (EVs) from 66 acute lymphoblastic leukemia (ALL) survivors and 61 healthy controls (254 samples in total). We then analyzed processes regulated by differentially expressed circulating miRNAs and cross-validated results with the data of patients with clinically manifested cardiomyopathies.

resultsWe found that especially miRNAs contained within EVs may be informative in terms of cardiomyopathy development and may regulate pathways related to neurotrophin signaling, transforming growth factor beta (TGFβ) or epidermal growth factor receptors (ErbB). We identified vesicular miR-144-3p and miR-423-3p as the most variable between groups and significantly correlated with echocardiographic parameters and, respectively, for plasma: let-7g-5p and miR-16-2-3p. Moreover, vesicular miR-144-3p correlates with the highest number of echocardiographic parameters and is differentially expressed in the circulation of patients with dilated cardiomyopathy. We also found that distribution of particular miRNAs between of plasma and EVs (proportion between compartments) e.g., miR-184 in ALL, is altered, suggesting changes within secretory and miRNA sorting mechanisms.

conclusionsOur results show that transcriptomic changes resulting from doxorubicin induced myocardial injury are reflected in circulating miRNA levels and precede development of the late onset cardiomyopathy phenotype. Among miRNAs related to cardiac function, we found vesicular miR-144-3p and miR-423-3p, as well as let-7g-5p and miR-16-2-3p contained in the total plasma. Selection of source for such studies (plasma or EVs) is of critical importance, as distribution of some miRNA between plasma and EVs is altered in ALL survivors, in comparison to healthy people, which suggests that doxorubicin-induced changes include miRNA sorting and export to extracellular space.

Indexed as

Circulating MicroRNAExtracellular VesiclesMicroRNAsCardiotoxicityDoxorubicinHumansCirculating MicroRNADoxorubicinMicroRNAsCardiotoxicityChildhood acute lymphoblastic leukemia (ALL)Clinical transcriptomicsDoxorubicinExtracellular vesicles (EVs)Micro-RNAs (miRNAs)

Identifiers

PMID36517751
PMCPMC9753431
OpenAlexW4311475740

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.